{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:58:22Z","timestamp":1781614702878,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breakthrough infections are defined as SARS-CoV-2 infections occurring\u2009\u2265\u200914 days after completing the primary COVID-19 vaccination series and remain a public health challenge, particularly in regions where immune-evasive variants are circulating. However, data on their virological and clinical profiles in low-resource settings are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study was conducted from July to December 2022 in Accra, Ghana, among individuals testing positive for SARS-CoV-2. Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) was performed using the Allplex\u2122 2019-nCoV Assay. Cycle threshold (Ct) values for the nucleocapsid (N), RNA-dependent RNA polymerase (RdRP), and envelope (E) genes, categorised as &lt;\u200925, 25\u201330, or &gt;\u200930. Variant identification targeted Alpha, Delta, and Omicron mutations using mutation-specific RT-PCR. Logistic regression was used to assess associations between vaccination status and demographic, clinical, and virological factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 268 samples analysed, 81 tested positive; 43.20% [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935] were vaccinated individuals. Median Ct-values for the N [27.13, IQR: 21.59\u201331.96] and E [24.57, IQR: 19.43\u201329.43] genes were significantly higher among vaccinated cases, indicating lower viral loads. Breakthrough infections were strongly associated with the Omicron variant [aOR\u2009=\u20094.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034]. Diarrhoea [aOR\u2009=\u20099.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022], sore throat [aOR\u2009=\u20098.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038], headache [aOR\u2009=\u200910.156,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039] and chills [aOR\u2009=\u20093.316,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046] were mostly associated with breakthrough infections. Ct-values of 25\u201330 [aOR\u2009=\u200911.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012] and &gt;\u200930 [aOR\u2009=\u20094.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047] were significantly associated with breakthrough infection compared to Ct\u2009&lt;\u200925 in breakthrough infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vaccinated individuals with SARS-CoV-2 infection had lower viral loads and were more likely to be infected with the Omicron variant. These findings reinforce the role of vaccination in reducing viral load and support the adoption of practical surveillance strategies, such as Ct value-based surveillance and variant screening in low middle-income countries facing similar constraints in genomic capacity and vaccine deployment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11732-6","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:32:04Z","timestamp":1760081524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cycle threshold values and SARS-CoV-2 variant associations with breakthrough infections: a retrospective study in Accra, Ghana"],"prefix":"10.1186","volume":"25","author":[{"given":"Frank Twum","family":"Aboagye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Annison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer Krampah","family":"Aidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maame Ekua","family":"Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Aryeetey","family":"Ashong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Bandoh","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrencia","family":"Osae-Nyarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Owusu-Frimpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Kwadwo","family":"Hackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Annison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenstar Dedei","family":"Quarshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena Konadu","family":"Owusu-Senyah Enninful","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naa Adjeley","family":"Kuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill Clinton","family":"Egyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Y.","family":"Osei-Atweneboana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"11732_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","volume":"70","author":"CDC","year":"2021","unstructured":"CDC. COVID-19 vaccine breakthrough infections reported to CDC \u2014 United States, January 1\u2013April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:792\u20133. https:\/\/doi.org\/10.15585\/mmwr.mm7021e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"11732_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(22)00152-0.","journal-title":"Lancet"},{"key":"11732_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/v14040827","volume":"14","author":"AS de Souza","year":"2022","unstructured":"de Souza AS, de Freitas Amorim VM, Guardia GDA, dos Santos FF, Ulrich H, Galante PAF, et al. Severe acute respiratory syndrome coronavirus 2 variants of concern: a perspective for emerging more transmissible and vaccine-resistant strains. Viruses. 2022;14:827. https:\/\/doi.org\/10.3390\/v14040827.","journal-title":"Viruses"},{"key":"11732_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102792","volume":"127","author":"A Haque","year":"2022","unstructured":"Haque A, Pant AB. Mitigating covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. J Autoimmun. 2022;127:102792. https:\/\/doi.org\/10.1016\/j.jaut.2021.102792.","journal-title":"J Autoimmun"},{"key":"11732_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.abg4493","volume":"371","author":"KD McCormick","year":"2021","unstructured":"McCormick KD, Jacobs JL, Mellors JW. The emerging plasticity of SARS-CoV-2. Science. 2021;371:1306\u20138. https:\/\/doi.org\/10.1126\/science.abg4493.","journal-title":"Science"},{"key":"11732_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.53854\/liim-2903-13","volume":"29","author":"A Abdulrahman","year":"2021","unstructured":"Abdulrahman A, Mallah SI, Alawadhi A, Perna S, Janahi EM, AlQahtani MM. Association between RT-PCR Ct values and COVID-19 new daily cases: a multicenter cross-sectional study. Infez Med. 2021;29:416\u201326. https:\/\/doi.org\/10.53854\/liim-2903-13.","journal-title":"Infez Med"},{"key":"11732_CR7","doi-asserted-by":"publisher","unstructured":"Bouzid D, Vila J, Hansen G, Manissero D, Pareja J, Rao SN et al. Systematic review on the association between respiratory virus real-time PCR cycle threshold values and clinical presentation or outcomes. J Antimicrob Chemother. 2021;76 Supplement_3:iii33\u201349. https:\/\/doi.org\/10.1093\/jac\/dkab246.","DOI":"10.1093\/jac\/dkab246."},{"key":"11732_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac135","volume":"9","author":"CB Acharya","year":"2022","unstructured":"Acharya CB, Schrom J, Mitchell AM, Coil DA, Marquez C, Rojas S, et al. Viral load among vaccinated and unvaccinated, asymptomatic and symptomatic persons infected with the SARS-CoV-2 delta variant. Open Forum Infect Dis. 2022;9:ofac135. https:\/\/doi.org\/10.1093\/ofid\/ofac135.","journal-title":"Open Forum Infect Dis"},{"key":"11732_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107362","volume":"153","author":"SP Andeweg","year":"2025","unstructured":"Andeweg SP, van de Kassteele J, Wang X, van Maarseveen N, Vlaemynck B, Bos S, et al. Estimating the effect of COVID-19 vaccination and prior infection on cycle threshold values as a proxy of SARS-CoV-2 viral load. Int J Infect Dis. 2025;153:107362. https:\/\/doi.org\/10.1016\/j.ijid.2024.107362.","journal-title":"Int J Infect Dis"},{"key":"11732_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40121-023-00772-7","volume":"12","author":"E Sala","year":"2023","unstructured":"Sala E, Shah IS, Manissero D, Juanola-Falgarona M, Quirke A-M, Rao SN. Systematic review on the correlation between SARS-CoV-2 real-time PCR cycle threshold values and epidemiological trends. Infect Dis Ther. 2023;12:749\u201375. https:\/\/doi.org\/10.1007\/s40121-023-00772-7.","journal-title":"Infect Dis Ther"},{"key":"11732_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2478\/jtim-2023-0118","volume":"11","author":"J Hyug Choi","year":"2023","unstructured":"Hyug Choi J, Sook Jun M, Yong Jeon J, Kim H-S, Kyung Kim Y, Ho Jeon C, et al. Global lineage evolution pattern of SARS-CoV-2 in Africa, America, Europe, and Asia: a comparative analysis of variant clusters and their relevance across continents. J Transl Intern Med. 2023;11:410\u201322. https:\/\/doi.org\/10.2478\/jtim-2023-0118.","journal-title":"J Transl Intern Med"},{"key":"11732_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/2993144","volume":"2024","author":"FT Aboagye","year":"2024","unstructured":"Aboagye FT, Annison L, Hackman HK, Acquah ME, Ashong Y, Owusu-Frimpong I, et al. Molecular epidemiology of SARS-CoV-2 within Accra metropolis postlockdown. Adv Virol. 2024;2024:e2993144. https:\/\/doi.org\/10.1155\/2024\/2993144.","journal-title":"Adv Virol"},{"key":"11732_CR13","doi-asserted-by":"publisher","first-page":"e43679","DOI":"10.7759\/cureus.43679","volume":"15","author":"A George","year":"2023","unstructured":"George A, Murugan T, Sampath S, N SM. Epidemiology of COVID-19 and the utility of cycle threshold (Ct) values in predicting the severity of disease. Cureus. 2023;15:e43679. https:\/\/doi.org\/10.7759\/cureus.43679.","journal-title":"Cureus"},{"key":"11732_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcvp.2023.100146","volume":"3","author":"S Natarajan","year":"2023","unstructured":"Natarajan S, Ranganathan M, Natarajan PL, Nesakumar M, Anbalagan S, Lucia Precilla K, et al. Comparison of real-time RT-PCR cycle threshold (Ct) values with clinical features and severity of COVID-19 disease among hospitalized patients in the first and second waves of COVID-19 pandemic in Chennai, India. Journal of Clinical Virology Plus. 2023;3:100146. https:\/\/doi.org\/10.1016\/j.jcvp.2023.100146.","journal-title":"Journal of Clinical Virology Plus"},{"key":"11732_CR15","unstructured":"CDC. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. Centers for Disease Control and Prevention. 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/guidelines-clinical-specimens.html. Accessed 25 Jan 2024."},{"key":"11732_CR16","first-page":"627","volume":"58","author":"LB Shrestha","year":"2020","unstructured":"Shrestha LB, Pokharel K. Standard operating procedure for specimen collection, packaging and transport for diagnosis of SARS-COV-2. JNMA J Nepal Med Assoc. 2020;58:627.","journal-title":"JNMA J Nepal Med Assoc"},{"key":"11732_CR17","doi-asserted-by":"publisher","unstructured":"Aboagye FT, Acquah ME. Isolation and amplification of SARS-CoV-2 RNA from nasopharyngeal specimen. Protoc Io. 2023;1\u20137. https:\/\/doi.org\/10.17504\/protocols.io.q26g7y32kgwz\/v1.","DOI":"10.17504\/protocols.io.q26g7y32kgwz\/v1"},{"key":"11732_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10096-020-04025-0","volume":"40","author":"FM Liotti","year":"2021","unstructured":"Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, et al. Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples. Eur J Clin Microbiol Infect Dis. 2021;40:269\u201377. https:\/\/doi.org\/10.1007\/s10096-020-04025-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11732_CR19","doi-asserted-by":"crossref","first-page":"e0269071","DOI":"10.1371\/journal.pone.0269071","volume":"17","author":"CN Umunnakwe","year":"2022","unstructured":"Umunnakwe CN, Makatini ZN, Maphanga M, Mdunyelwa A, Mlambo KM, Manyaka P, et al. Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings. PLoS ONE. 2022;17:e0269071.","journal-title":"PLoS ONE"},{"key":"11732_CR20","doi-asserted-by":"publisher","first-page":"e02922","DOI":"10.1128\/spectrum.02922-22","volume":"10","author":"FM Liotti","year":"2022","unstructured":"Liotti FM, De Maio F, Ippoliti C, Santarelli G, Monzo FR, Sali M, et al. Two-period study results from a large Italian hospital laboratory attesting SARS-CoV-2 variant PCR assay evolution. Microbiol Spectr. 2022;10:e02922-22. https:\/\/doi.org\/10.1128\/spectrum.02922-22.","journal-title":"Microbiol Spectr"},{"issue":"5","key":"11732_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jmoldx.2022.02.001","volume":"24","author":"MC Nielsen","year":"2022","unstructured":"Nielsen MC, Machado RRG, Mitchell BM, McConnell AJ, Saada NI, Weaver SC, et al. A comparison of seegene technologies Novaplex SARS-CoV-2 variants I, II, and IV assays with Spike gene sequencing for detection of known severe acute respiratory syndrome coronavirus 2 variants. J Mol Diagn. 2022;24(5):455\u201361. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.02.001.","journal-title":"J Mol Diagn"},{"issue":"783","key":"11732_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq1086","volume":"17","author":"L Chan","year":"2025","unstructured":"Chan L, Pinedo K, Stabile MA, Hamlin RE, Pienkos SM, Ratnasiri K, et al. Prior vaccination prevents overactivation of innate immune responses during COVID-19 breakthrough infection. Sci Transl Med. 2025;17(783):eadq1086. https:\/\/doi.org\/10.1126\/scitranslmed.adq1086.","journal-title":"Sci Transl Med"},{"key":"11732_CR23","doi-asserted-by":"publisher","first-page":"e1011308","DOI":"10.1371\/journal.ppat.1011308","volume":"19","author":"X Yu","year":"2023","unstructured":"Yu X, Juraszek J, Rutten L, Bakkers MJG, Blokland S, Melchers JM, et al. Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 Spike. PLoS Pathog. 2023;19:e1011308. https:\/\/doi.org\/10.1371\/journal.ppat.1011308.","journal-title":"PLoS Pathog"},{"key":"11732_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1186\/s12879-025-11107-x","volume":"25","author":"AM Aga","year":"2025","unstructured":"Aga AM, Mulugeta D, Gebreegziabxier A, Zeleke GT, Girmay AM, Tura GB, et al. Genome diversity of SARS-CoV-2 lineages associated with vaccination breakthrough infections in Addis Ababa, Ethiopia. BMC Infect Dis. 2025;25:738. https:\/\/doi.org\/10.1186\/s12879-025-11107-x.","journal-title":"BMC Infect Dis"},{"key":"11732_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1186\/s12879-024-09902-z","volume":"24","author":"A Karmacharya","year":"2024","unstructured":"Karmacharya A, Rai K, Siwakoti S, Khanal B, Bhattarai NR. COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal. BMC Infect Dis. 2024;24:1003. https:\/\/doi.org\/10.1186\/s12879-024-09902-z.","journal-title":"BMC Infect Dis"},{"key":"11732_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12879-025-10530-4","volume":"25","author":"B Maleki","year":"2025","unstructured":"Maleki B, Sadeghian AM, Ranjbar M. Impact of vaccination against SARS-CoV-2 on mortality risk, ICU admission rate, and hospitalization length in hospitalized COVID-19 patients: a cross-sectional study. BMC Infect Dis. 2025;25:144. https:\/\/doi.org\/10.1186\/s12879-025-10530-4.","journal-title":"BMC Infect Dis"},{"key":"11732_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.670","volume":"10","author":"R Duan","year":"2022","unstructured":"Duan R, Mao Q, Ding X, Qiu Q, Wang P. Immunologic features of asymptomatic postvaccination infections with the delta variant of SARS-CoV\u20102 in adults. Immun Inflamm Dis. 2022;10:e670. https:\/\/doi.org\/10.1002\/iid3.670.","journal-title":"Immun Inflamm Dis"},{"key":"11732_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12982-024-00236-4","volume":"21","author":"CS Frempong","year":"2024","unstructured":"Frempong CS, Tarkang EE, Amu H, Gborglah M, Salu S, Otoo DM. Prevalence and factors associated with COVID-19 vaccine hesitancy among adults in Ghana: a population-based cross-sectional study in the Volta region. Discov Public Health. 2024;21:126. https:\/\/doi.org\/10.1186\/s12982-024-00236-4.","journal-title":"Discov Public Health"},{"key":"11732_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41182-023-00519-7","volume":"51","author":"RNE McCarthy","year":"2023","unstructured":"McCarthy RNE, Donkoh ET, Arthur DD, Dassah ET, Boadu KO, Otoo JE, et al. Public relations strategies employed by the Ghana health service to address COVID-19 vaccine hesitancy: a qualitative inquiry. Trop Med Health. 2023;51:26. https:\/\/doi.org\/10.1186\/s41182-023-00519-7.","journal-title":"Trop Med Health"},{"key":"11732_CR30","doi-asserted-by":"publisher","first-page":"e1011461","DOI":"10.1371\/journal.ppat.1011461","volume":"19","author":"HR Fryer","year":"2023","unstructured":"Fryer HR, Golubchik T, Hall M, Fraser C, Hinch R, Ferretti L, et al. Viral burden is associated with age, vaccination, and viral variant in a population-representative study of SARS-CoV-2 that accounts for time-since-infection-related sampling bias. PLoS Pathog. 2023;19:e1011461. https:\/\/doi.org\/10.1371\/journal.ppat.1011461.","journal-title":"PLoS Pathog"},{"key":"11732_CR31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41591-021-01316-7","volume":"27","author":"M Levine-Tiefenbrun","year":"2021","unstructured":"Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27:790\u20132.","journal-title":"Nat Med"},{"key":"11732_CR32","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1002\/anie.202015362","volume":"60","author":"S Jangra","year":"2021","unstructured":"Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A, et al. Sterilizing immunity against SARS-CoV\u20102 infection in mice by a single\u2010shot and lipid amphiphile imidazoquinoline TLR7\/8 agonist\u2010adjuvanted recombinant spike protein vaccine. Angew Chem Int Ed. 2021;60:9467\u201373. https:\/\/doi.org\/10.1002\/anie.202015362.","journal-title":"Angew Chem Int Ed"},{"key":"11732_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1128\/JVI.01535-09","volume":"84","author":"JA Rutigliano","year":"2010","unstructured":"Rutigliano JA, Morris MY, Yue W, Keating R, Webby RJ, Thomas PG, et al. Protective memory responses are modulated by priming events prior to challenge. J Virol. 2010;84:1047\u201356. https:\/\/doi.org\/10.1128\/JVI.01535-09.","journal-title":"J Virol"},{"key":"11732_CR34","doi-asserted-by":"publisher","first-page":"e1010802","DOI":"10.1371\/journal.ppat.1010802","volume":"18","author":"M Garcia-Knight","year":"2022","unstructured":"Garcia-Knight M, Anglin K, Tassetto M, Lu S, Zhang A, Goldberg SA, et al. Infectious viral shedding of SARS-CoV-2 delta following vaccination: a longitudinal cohort study. PLoS Pathog. 2022;18:e1010802. https:\/\/doi.org\/10.1371\/journal.ppat.1010802.","journal-title":"PLoS Pathog"},{"key":"11732_CR35","doi-asserted-by":"publisher","first-page":"e01973","DOI":"10.1128\/jvi.01973-21","volume":"96","author":"RM Burckhardt","year":"2022","unstructured":"Burckhardt RM, Dennehy JJ, Poon LLM, Saif LJ, Enquist LW. Are COVID-19 vaccine boosters needed? The science behind boosters. J Virol. 2022;96:e01973\u201321. https:\/\/doi.org\/10.1128\/jvi.01973-21.","journal-title":"J Virol"},{"key":"11732_CR36","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/jmv.27590","volume":"94","author":"H Meng","year":"2022","unstructured":"Meng H, Mao J, Ye Q. Booster vaccination strategy: necessity, immunization objectives, immunization strategy, and safety. J Med Virol. 2022;94:2369\u201375. https:\/\/doi.org\/10.1002\/jmv.27590.","journal-title":"J Med Virol"},{"key":"11732_CR37","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. https:\/\/doi.org\/10.1126\/science.abm0829.","journal-title":"Science"},{"key":"11732_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-022-00753-2","volume":"12","author":"N Pooley","year":"2023","unstructured":"Pooley N, Abdool Karim SS, Combadi\u00e8re B, Ooi EE, Harris RC, El Guerche Seblain C, et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infect Dis Ther. 2023;12:367\u201387. https:\/\/doi.org\/10.1007\/s40121-022-00753-2.","journal-title":"Infect Dis Ther"},{"key":"11732_CR39","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177\u20139. https:\/\/doi.org\/10.1056\/NEJMc2001737.","journal-title":"N Engl J Med"},{"key":"11732_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(20)30985-3","volume":"21","author":"M Marks","year":"2021","unstructured":"Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monn\u00e9 M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21:629\u201336. https:\/\/doi.org\/10.1016\/S1473-3099(20)30985-3.","journal-title":"Lancet Infect Dis"},{"key":"11732_CR41","doi-asserted-by":"publisher","first-page":"eabh0635","DOI":"10.1126\/science.abh0635","volume":"373","author":"JA Hay","year":"2021","unstructured":"Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al. Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science. 2021;373:eabh0635. https:\/\/doi.org\/10.1126\/science.abh0635.","journal-title":"Science"},{"key":"11732_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12879-023-08363-0","volume":"23","author":"OS Almalki","year":"2023","unstructured":"Almalki OS, Santali EY, Alhothali AA, Ewis AA, Shady A, Fathelrahman AI, et al. The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines. BMC Infect Dis. 2023;23:378. https:\/\/doi.org\/10.1186\/s12879-023-08363-0.","journal-title":"BMC Infect Dis"},{"key":"11732_CR43","doi-asserted-by":"publisher","first-page":"e01256","DOI":"10.1128\/spectrum.01256-23","volume":"11","author":"S Shahbaz","year":"2023","unstructured":"Shahbaz S, Bozorgmehr N, Lu J, Osman M, Sligl W, Tyrrell DL, et al. Analysis of SARS-CoV-2 isolates, namely the Wuhan strain, delta variant, and Omicron variant, identifies differential immune profiles. Microbiol Spectr. 2023;11:e01256\u201323. https:\/\/doi.org\/10.1128\/spectrum.01256-23.","journal-title":"Microbiol Spectr"},{"key":"11732_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s44197-023-00146-9","volume":"13","author":"HM Adly","year":"2023","unstructured":"Adly HM, Saleh SAK, Garout MA, Abdulkhaliq AA, Khafagy AA, Saati AA, et al. Post COVID-19 symptoms among infected vaccinated individuals: a cross-sectional study in Saudi Arabia. J Epidemiol Glob Health. 2023;13:740\u201350. https:\/\/doi.org\/10.1007\/s44197-023-00146-9.","journal-title":"J Epidemiol Glob Health"},{"key":"11732_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101212","author":"LS Canas","year":"2021","unstructured":"Canas LS, \u00d6sterdahl MF, Deng J, Hu C, Selvachandran S, Polidori L, et al. Disentangling post-vaccination symptoms from early COVID-19. eClinicalMedicine. 2021. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101212.","journal-title":"eClinicalMedicine"},{"key":"11732_CR46","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/jmv.27635","volume":"94","author":"S Daria","year":"2022","unstructured":"Daria S, Islam MR. The SARS-CoV\u20102 omicron wave is indicating the end of the pandemic phase but the COVID\u201019 will continue. J Med Virol. 2022;94:2343\u20135. https:\/\/doi.org\/10.1002\/jmv.27635.","journal-title":"J Med Virol"},{"key":"11732_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12879-023-08527-y","volume":"23","author":"A Kandeel","year":"2023","unstructured":"Kandeel A, Moatasim Y, Fahim M, Bahaaeldin H, El-Shesheny R, Roshdy WH, et al. Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020\u20132022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality. BMC Infect Dis. 2023;23:542. https:\/\/doi.org\/10.1186\/s12879-023-08527-y.","journal-title":"BMC Infect Dis"},{"key":"11732_CR48","doi-asserted-by":"publisher","first-page":"e00109","DOI":"10.1128\/jvi.00109-25","volume":"99","author":"B Dadonaite","year":"2025","unstructured":"Dadonaite B, Burrell AR, Logue J, Chu HY, Payne DC, Haslam DB, et al. SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals. J Virol. 2025;99:e00109\u201325. https:\/\/doi.org\/10.1128\/jvi.00109-25.","journal-title":"J Virol"},{"key":"11732_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.04.023","volume":"85","author":"P Pandit","year":"2022","unstructured":"Pandit P, Bhatt P, Sahay RR, Joshi Y, Patil DY, Yadav PD. A case of breakthrough infection with SARS-CoV-2 delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional. J Infect. 2022;85:e15. https:\/\/doi.org\/10.1016\/j.jinf.2022.04.023.","journal-title":"J Infect"},{"key":"11732_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.36437\/irmhs.2024.7.2.B","volume":"7","author":"RC Kafwanka","year":"2024","unstructured":"Kafwanka RC, Chipimo M, Incidence. Risk Factors, and outcomes of severe breakthrough COVID-19 infections among hospitalized patients in Africa. Int Res Med Health Sci. 2024;7:7\u201321. https:\/\/doi.org\/10.36437\/irmhs.2024.7.2.B.","journal-title":"Int Res Med Health Sci"},{"key":"11732_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab986","volume":"75","author":"C Huai Luo","year":"2021","unstructured":"Huai Luo C, Paul Morris C, Sachithanandham J, Amadi A, Gaston DC, Li M, et al. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is associated with higher recovery of infectious virus compared to the alpha variant in both unvaccinated and vaccinated individuals. Clin Infect Dis. 2021;75:e715\u201325. https:\/\/doi.org\/10.1093\/cid\/ciab986.","journal-title":"Clin Infect Dis"},{"key":"11732_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.797589","author":"T Tada","year":"2022","unstructured":"Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Herati RS, et al. Neutralization of SARS-CoV-2 variants by mRNA and adenoviral vector vaccine-elicited antibodies. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.797589.","journal-title":"Front Immunol"},{"key":"11732_CR53","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.abg9175","volume":"372","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413\u20138. https:\/\/doi.org\/10.1126\/science.abg9175.","journal-title":"Science"},{"key":"11732_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152702","author":"R Duerr","year":"2021","unstructured":"Duerr R, Dimartino D, Marier C, Zappile P, Wang G, Lighter J, et al. Dominance of alpha and iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI152702.","journal-title":"J Clin Invest"},{"key":"11732_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1027271","author":"J Dingemans","year":"2022","unstructured":"Dingemans J, van der Veer BMJW, Gorgels KMF, Hackert V, den Heijer CDJ, Hoebe CJPA, et al. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Front Microbiol. 2022. https:\/\/doi.org\/10.3389\/fmicb.2022.1027271.","journal-title":"Front Microbiol"},{"key":"11732_CR56","doi-asserted-by":"publisher","first-page":"e0003770","DOI":"10.1371\/journal.pgph.0003770","volume":"4","author":"AF Asare","year":"2024","unstructured":"Asare AF, Sabblah GT, Buabeng RO, Alhassan Y, Asamoa-Amoakohene A, Amponsa-Achiano K, et al. Adverse events following COVID-19 vaccination: a comprehensive analysis of spontaneous reporting data in Ghana. PLOS Glob Public Health. 2024;4:e0003770. https:\/\/doi.org\/10.1371\/journal.pgph.0003770.","journal-title":"PLOS Glob Public Health"},{"key":"11732_CR57","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.abq0203","volume":"377","author":"JE Bowen","year":"2022","unstructured":"Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 2022;377:890\u20134. https:\/\/doi.org\/10.1126\/science.abq0203.","journal-title":"Science"},{"key":"11732_CR58","doi-asserted-by":"publisher","first-page":"R918","DOI":"10.1016\/j.cub.2021.06.049","volume":"31","author":"SP Otto","year":"2021","unstructured":"Otto SP, Day T, Arino J, Colijn C, Dushoff J, Li M, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021;31:R918\u201329. https:\/\/doi.org\/10.1016\/j.cub.2021.06.049.","journal-title":"Curr Biol"},{"key":"11732_CR59","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2478\/jtim-2023-0122","volume":"11","author":"J Xie","year":"2023","unstructured":"Xie J, Ye F, Deng X, Tang Y, Liang J-Y, Huang X, et al. Circular RNA: a promising new star of vaccine. J Transl Intern Med. 2023;11:372\u201381. https:\/\/doi.org\/10.2478\/jtim-2023-0122.","journal-title":"J Transl Intern Med"},{"key":"11732_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.02.033","volume":"84","author":"M Bongiovanni","year":"2022","unstructured":"Bongiovanni M, Spada E, De Angelis C, Liuzzi G, Giuliani G. SARS-CoV-2 re-infection, vaccination and neutralizing antibodies. J Infect. 2022;84:e120\u20131. https:\/\/doi.org\/10.1016\/j.jinf.2022.02.033.","journal-title":"J Infect"},{"key":"11732_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1515\/mr-2024-0013","volume":"4","author":"M Guo","year":"2024","unstructured":"Guo M, Shang S, Li M, Cai G, Li P, Chen X, et al. Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis\/mechanisms of long COVID. Med Rev 2021. 2024;4:367\u201383. https:\/\/doi.org\/10.1515\/mr-2024-0013.","journal-title":"Med Rev 2021"},{"key":"11732_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1515\/mr-2024-0030","volume":"5","author":"AG Ewing","year":"2025","unstructured":"Ewing AG, Salamon S, Pretorius E, Joffe D, Fox G, Bilodeau S, et al. Review of organ damage from COVID and long COVID: a disease with a spectrum of pathology. Med Rev 2021. 2025;5:66\u201375. https:\/\/doi.org\/10.1515\/mr-2024-0030.","journal-title":"Med Rev 2021"}],"updated-by":[{"DOI":"10.1186\/s12879-025-11965-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11732-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:25:12Z","timestamp":1781612712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11732"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11732-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-025-11965-5","URL":"https:\/\/doi.org\/10.1186\/s12879-025-11965-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved a secondary analysis of anonymised data originally collected under the study \u201cMolecular Epidemiology of SARS-CoV-2 in the Accra Metropolis,\u201d which received ethical approval from the Ethical Review Committee of the Department of Medical Laboratory Technology, Accra Technical University (Protocol number: ATU\/MLT\/ET\/01192304B\/2021\u20132022). The current analysis forms part of a planned extension of that original study. The original protocol explicitly permitted further analysis of the collected data for related investigations into SARS-CoV-2 viral dynamics and variant characteristics. The original study included written informed consent from participants at the time of sample collection, in accordance with institutional procedures. The current retrospective analysis was conducted using fully anonymised clinical and laboratory data, including cycle threshold values and variant typing results. In line with the ethics committee\u2019s guidelines, individual informed consent for this secondary analysis was waived. The study was conducted in accordance with the principles of the Declaration of Helsinki and complied with all applicable institutional and national ethical standards governing human research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable. This study involved secondary analysis of fully anonymised data, and no individual person\u2019s data in any form (including images or identifiable information) are included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}}],"article-number":"1269"}}